SEHK:1696

Stock Analysis Report

Executive Summary

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.

Snowflake

Fundamentals

Undervalued with excellent balance sheet.

Risks

  • Sisram Medical is not covered by any analysts.

Similar Companies

Share Price & News

How has Sisram Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

1696

0.6%

HK Medical Equipment

-2.7%

HK Market


1 Year Return

-21.3%

1696

-1.6%

HK Medical Equipment

-9.4%

HK Market

1696 underperformed the Medical Equipment industry which returned -1.6% over the past year.

1696 underperformed the Market in Hong Kong which returned -9.4% over the past year.


Share holder returns

1696IndustryMarket
7 Day-0.7%0.6%-2.7%
30 Day21.3%20.6%2.4%
90 Day4.8%23.9%-5.6%
1 Year-19.2%-21.3%-0.5%-1.6%-6.2%-9.4%
3 Yearn/a21.5%17.6%14.3%2.7%
5 Yearn/a0.9%-4.2%16.7%-2.8%

Price Volatility Vs. Market

How volatile is Sisram Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Examining Sisram Medical Ltd’s (HKG:1696) Weak Return On Capital Employed

Valuation

Is Sisram Medical undervalued based on future cash flows and its price relative to the stock market?

41%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Sisram Medical's share price is below the future cash flow value, and at a moderate discount (> 20%).

Sisram Medical's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Sisram Medical is good value based on earnings compared to the HK Medical Equipment industry average.

Sisram Medical is good value based on earnings compared to the Hong Kong market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Sisram Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Sisram Medical is good value based on assets compared to the HK Medical Equipment industry average.


Next Steps

Future Growth

How is Sisram Medical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Sisram Medical is high growth as no revenue estimate data is available.

Sisram Medical's earnings are expected to grow by 15.9% yearly, however this is not considered high growth (20% yearly).

Unable to compare Sisram Medical's revenue growth to the Hong Kong market average as no estimate data is available.

Sisram Medical's earnings growth is expected to exceed the Hong Kong market average.

Sisram Medical's earnings growth is expected to exceed the low risk savings rate of 2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Sisram Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Sisram Medical performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sisram Medical has delivered over 20% year on year earnings growth in the past 5 years.

Sisram Medical's 1-year earnings growth exceeds its 5-year average (64.2% vs 30.2%)

Sisram Medical's earnings growth has exceeded the HK Medical Equipment industry average in the past year (64.2% vs 50.2%).


Return on Equity

Sisram Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Sisram Medical used its assets less efficiently than the HK Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Sisram Medical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Sisram Medical's financial position?


Financial Position Analysis

Sisram Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sisram Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Sisram Medical's level of debt (0.9%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Sisram Medical's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (735.9%, greater than 20% of total debt).

Sisram Medical earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 66.6x debt.


Next Steps

Dividend

What is Sisram Medical's current dividend yield, its reliability and sustainability?

2.46%

Current Dividend Yield


Dividend Yield and Payments Analysis

Sisram Medical's pays a higher dividend yield than the bottom 25% of dividend payers in Hong Kong (2.21%).

Sisram Medical's dividend is below the markets top 25% of dividend payers in Hong Kong (6.17%).

It is too early to tell whether Sisram Medical has stable dividend payments.

Sisram Medical only just started paying a dividend, it is too early to tell if payments are increasing.


Current Payout to Shareholders

Dividends paid are well covered by earnings (4.1x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Sisram Medical's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Lior Dayan (49yo)

2.3yrs

Tenure

US$884,000

Compensation

Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and is responsible for its overall and day-to-day management and development. Mr. Dayan ...


CEO Compensation Analysis

Lior's remuneration is higher than average for companies of similar size in Hong Kong.

Lior's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.5yrs

Average Tenure

50.5yo

Average Age

The average tenure for the Sisram Medical management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.1yrs

Average Tenure

44.5yo

Average Age

The average tenure for the Sisram Medical board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Sisram Medical individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$308,37216 Jul 19
Lior Dayan
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares77,500
Max PriceUS$3.98

Ownership Breakdown


Management Team

  • Susan Lo (61yo)

    Company Secretary

    • Tenure: 2.3yrs
  • Liu Yi (43yo)

    Executive Chairman

    • Tenure: 3.4yrs
  • Lior Dayan (49yo)

    CEO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: US$884.00k
  • Avraham Farbstein (64yo)

    Chief Strategy Officer

    • Tenure: 1.5yrs
  • Ran Ezioni (52yo)

    Chief Operating Officer

    • Tenure: 1.4yrs
  • Guojun Bu (43yo)

    CFO & Executive Director

    • Tenure: 0.7yrs

Board Members

  • Addy Fong (60yo)

    Independent Non-Executive Director

    • Tenure: 2.1yrs
    • Compensation: US$25.00k
  • Yifang Wu (50yo)

    Non-Executive Director

    • Tenure: 2.9yrs
  • Yao Wang (46yo)

    Non-Executive Director

    • Tenure: 3.4yrs
  • Liu Yi (43yo)

    Executive Chairman

    • Tenure: 3.4yrs
  • Lior Dayan (49yo)

    CEO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: US$884.00k
  • Leo Chan (40yo)

    Independent Non-Executive Director

    • Tenure: 2.1yrs
    • Compensation: US$25.00k
  • Jenny Chen (40yo)

    Independent Non-Executive Director

    • Tenure: 2.1yrs
    • Compensation: US$25.00k
  • Kenneth Liu (49yo)

    Independent Non-Executive Director

    • Tenure: 2.1yrs
    • Compensation: US$25.00k
  • Guojun Bu (43yo)

    CFO & Executive Director

    • Tenure: 0.7yrs
  • Dai Kun (42yo)

    Non-Executive Director

    • Tenure: 0.08yrs

Company Information

Sisram Medical Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sisram Medical Ltd
  • Ticker: 1696
  • Exchange: SEHK
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: HK$1.835b
  • Shares outstanding: 442.16m
  • Website: https://www.sisram-medical.com

Number of Employees


Location

  • Sisram Medical Ltd
  • 14 Halamish Street
  • Caesarea Industrial Park
  • Caesarea
  • 38900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1696SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDSep 2017

Biography

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North Amer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 12:52
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.